Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma
Launched by MARWA MAHMOUD HASSAN · Apr 5, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
To correlate different levels of c-MYC expressions with variable clinical and pathological parameters of mammary carcinoma (such as patients' ages, tumor grading, staging, laterality, focality and nodal metastasis, co-existing in-situ components). This study will be carried out on archived formalin-fixed and paraffin embedded tissue blocks that were belonged to 70 women with breast lumps.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Specimens of Modified Radical Mastectomies from breast carcinoma patients
- Exclusion Criteria:
- • Cases with insufficient clinical data.
- • Tissue blocks of destroyed or insufficient material, unfit for diagnosis.
- • Cases who received pre-operative chemotherapy.
About Marwa Mahmoud Hassan
Marwa Mahmoud Hassan is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong background in clinical development and a focus on innovative therapeutic solutions, Ms. Hassan leads initiatives that prioritize ethical standards and regulatory compliance. Her strategic approach fosters collaboration among multidisciplinary teams, ensuring efficient study design and execution. Through robust data analysis and a patient-centered philosophy, she aims to contribute significantly to the advancement of healthcare solutions that address critical unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sohag, , Egypt
Patients applied
Trial Officials
Afaf Alnashar, professor
Principal Investigator
Sohag University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported